Cellectis bioresearch and Syngene Announce Partnership on the Development of Customized Cell Lines

Regulatory News:

Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis (Paris:ALCLS), and Syngene International Ltd, an internationally reputed contract research and manufacturing services (CRAMS) organization and subsidiary of BIOCON Ltd, India’s largest biotechnology company by revenue, announced today that they have entered into an agreement to develop novel genetically customized cell lines.

This partnership between Cellectis bioresearch and Syngene will leverage Cellectis’ patented technology in genome customization with Syngene’s strong biology platform and capabilities to develop novel recombinant and knock-out cell lines for use in oncology- and ADME-Tox-based drug discovery studies.

"This new partnership with Syngene International will enable us to mobilize each organization‘s expertise and know-how and create synergies that will deliver hundreds of engineered cell lines for drug discovery and functional genomics” said Marc Le Bozec, Chief Executive Officer, Cellectis bioresearch.

Peter Bains, Chief Operating Officer, Syngene International said, "We are very pleased to enter into this strategic collaboration with Cellectis bioresearch. This is a very exciting R&D arena, employing state-of-the-art technologies, and we are delighted to have the opportunity to support Cellectis’ goals through our biology platform at Syngene.’’

About Cellectis bioresearch
Established in 2008 as a subsidiary of Cellectis, Cellectis bioresearch provides life sciences researchers with genome customization tools and services, such as the award-winning TALEN® Access™. The company also develops and markets genetically customized cells with characteristics and performances adapted to three main markets: drug discovery, gene function studies and protein production.
For further information, please visit www.cellectis-bioresearch.com

About Syngene International Limited
Established in 1994 as a subsidiary of Biocon Limited, Syngene is an internationally reputed custom research and manufacturing company with multi-disciplinary skills in integrated drug discovery and development, with capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D and formulation development for both small and large molecules. Over the past 16+ years, Syngene has successfully partnered with leading players in the global pharmaceutical industry offering its services across drug discovery/ development continuum. Syngene has over 1500 scientists and is well-equipped to offer its world class services to its customers from early stage discovery and preclinical development through clinical development (Phase I-III) till commercial manufacturing requirements for small and large molecules in the most efficient manner in terms of cost, quality and time.
For further information, please visit www.syngeneintl.com.